— UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...

GSK, Sanofi and Boehringer Ingelheim. Last month, Sanofi reached an agreement in principle to settle 4,000 lawsuits linking ...

GSK has opted to settle a key lawsuit ... will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer.

A recent ruling has determined a $2.2 billion payout to settle 93% of cases ... Thousands of lawsuits have been filed against GSK, claiming their antacid Zantac caused a greater risk of cancer ...

The three-day hearing comes a few months after GSK decided to settle a complaint brought ... The common claim in the lawsuits is that a contaminant in Zantac (ranitidine) called N ...

GSK last month agreed to settle about 80,000 Zantac lawsuits, representing most of the litigation against it, for $2.2 billion. Pfizer has also agreed to settle most of the outstanding cases ...

GSK plc (NYSE:GSK) – GSK agreed to pay up to $2.2 billion to settle 93% of U.S. lawsuits related to Zantac, alleging the drug caused cancer. The settlement, announced Wednesday, was lower than ...

The lawsuits arose after recipients of GSK’s heartburn drug Zantac claimed it caused cancer. Chief executive Emma Walmsey said the move to settle around 80,000 lawsuits across the US – covering about ...

Thousands of lawsuits have been filed against GSK, claiming their antacid Zantac caused a greater risk ... was in the company's fiscal interest to settle the lawsuits in order to appease ...